Caroline B 3/10/22 Caroline B 3/10/22

Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round

Austin, TX – March 10, 2022 – Maxwell has developed a groundbreaking drug platform technology with the potential to profoundly impact global health. This funding will accelerate our efforts to develop a new class of drugs designed to fight viruses and other pathogens.

Joshua McClure 2/28/22 Joshua McClure 2/28/22

Maxwell Biosciences Awarded “Most Promising” 2022 Life Sciences Company in Texas Competition

Caroline B 2/23/22 Caroline B 2/23/22

New Research Published in ACS Infectious Diseases Examines Impact of Self-Assembly of Antimicrobial Peptoids on ESKAPE Bacterial Pathogens

Joshua McClure 7/1/21 Joshua McClure 7/1/21

Turning Nature’s Virus Fighters Into Powerful Drugs: Synthetic “Peptoids” to Cure Diseases

Guest User 6/7/21 Guest User 6/7/21

ViewPoints Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2

Guest User 6/1/21 Guest User 6/1/21

Stanford Engineering magazine profiles Dr. Annelise Barron: A bioengineer aims to turn nature's virus into powerful drugs

Guest User 5/18/21 Guest User 5/18/21

Maxwell Biosciences Announces the CLAROMER® Brand Biotech Therapeutics Platform as It Advances Toward Clinical Trials

Guest User 4/7/21 Guest User 4/7/21

David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs

Guest User 4/5/21 Guest User 4/5/21

New research published in Pharmaceuticals (MDPI) demonstrates that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2

Guest User 3/23/21 Guest User 3/23/21

NPR Webcast featuring Maxwell Biosciences Chief Scientific Officer: Science, Rhetoric and Society

Guest User 3/10/21 Guest User 3/10/21

MEDIA ADVISORY:Maxwell Biosciences to Present at the Upcoming 2021 Spring Private Company Showcase Hosted by Credit Suisse, Solebury Trout, and Cooley

Guest User 3/3/21 Guest User 3/3/21

Maxwell Biosciences Appoints Kent Kirshenbaum, Ph.D. as Chief Scientific Officer and Sheetal Vali, Ph.D. as Director of Drug Development

Joshua McClure 6/11/19 Joshua McClure 6/11/19

Maxwell Focus: Next Generation Anti-infectives

Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round

Maxwell Biosciences Awarded “Most Promising” 2022 Life Sciences Company in Texas Competition

New Research Published in ACS Infectious Diseases Examines Impact of Self-Assembly of Antimicrobial Peptoids on ESKAPE Bacterial Pathogens

Turning Nature’s Virus Fighters Into Powerful Drugs: Synthetic “Peptoids” to Cure Diseases

ViewPoints Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2

Stanford Engineering magazine profiles Dr. Annelise Barron: A bioengineer aims to turn nature's virus into powerful drugs

Maxwell Biosciences Announces the CLAROMER® Brand Biotech Therapeutics Platform as It Advances Toward Clinical Trials

David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs

New research published in Pharmaceuticals (MDPI) demonstrates that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2

NPR Webcast featuring Maxwell Biosciences Chief Scientific Officer: Science, Rhetoric and Society

MEDIA ADVISORY:Maxwell Biosciences to Present at the Upcoming 2021 Spring Private Company Showcase Hosted by Credit Suisse, Solebury Trout, and Cooley

Maxwell Biosciences Appoints Kent Kirshenbaum, Ph.D. as Chief Scientific Officer and Sheetal Vali, Ph.D. as Director of Drug Development

Maxwell Focus: Next Generation Anti-infectives

Maxwell Biosciences, Inc.

Company

News

Science